MERGE
30.4.2024 10:01:35 CEST | Business Wire | Press release
Merge, which provides unified APIs for B2B SaaS organizations to easily add hundreds of integrations to their products, has officially expanded to Europe with the establishment of its Berlin-based team. The expansion reinforces Merge’s commitment to serving European customers’ integration wants and needs effectively.
Data protection has been a top priority for European organizations since The General Data Protection Regulation (GDPR) took effect in 2018. As a result, Merge remains steadfast in prioritizing investments in security, product infrastructure, and support to assist European companies with their product integration needs.
To ensure the highest standards of security and compliance, Merge maintains ISO 27001 and SOC 2 Type 2 certifications. Additionally, Merge puts in place Data Processing Agreements (DPAs) with all customers, committing to processing data transfers in accordance with GDPR’s Standard Contractual Clauses. Furthermore, Merge supports both multi-tenant and single-tenant environments, enabling customers to fully control where their end-user data is stored.
“We know how important it is for our European customers to securely and quickly offer customer-facing integrations, which is why we’ve prioritized building and enhancing our infrastructure, security-focused features, and Europe-based software integrations,” said Shensi Ding, co-founder and CEO of Merge. “With our new team based in Berlin, we have even faster, dedicated support, providing our customers everything they need to securely and confidently use Merge.”
Merge is proud to be trusted by hundreds of Europe-based companies, including Eloomi, Payhawk, Staffbase, Hofy, TravelPerk, Ledgy, and Causal. Today, 30% of Merge’s customers are based in Europe, and these investments are aimed at better serving this market. Currently offering 200+ global integrations, Merge is focused on adding European providers as it continues to scale.
"Ledgy is being used by organizations in 45+ countries, and Merge has helped us along the way,” said Armon Bättig, head of sales at Zürich-based Ledgy - an equity management platform that uses Merge to power its HRIS integrations.
To learn more about Merge’s integrations for GDPR-compliant companies, visit: www.merge.dev/eu
European companies can visit the Merge booth at Pendomonium’s Mind the Product in London on June 20th, Berlin on June 27th, and at SaaStock in Dublin on October 14th.
About Merge:
Merge is a product integration platform that offers a suite of unified APIs to empower B2B SaaS organizations to seamlessly add hundreds of integrations to their apps. Merge’s platform makes secure data access easy by offering unified APIs across key software categories, including HRIS, accounting, CRM, file storage, and more. By handling the full integration lifecycle, Merge empowers companies to close deals faster, reduce customer churn, and save engineering costs.
Merge is backed by Accel Partners, New Enterprise Associates (NEA), and Addition, and has received $75 million in funding. Merge was founded in 2020 by Shensi Ding and Gil Feig and has offices in San Francisco, New York City and Berlin. For more information, visit Merge's website and follow the company on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430162409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom